Why You Don't Need to Cycle CJC-1295 or Tesamorelin

Your pituitary gland runs two completely separate growth hormone release systems, and almost every cycling protocol online treats them as one.

That mistake matters because it leads people to either cycle things that don't need cycling or skip the cycling on things that do. To understand why, you need to see the full chain first.

Growth hormone doesn't just release on its own. Your hypothalamus sends signals down to your pituitary, and the pituitary responds by pulsing growth hormone into your bloodstream. That growth hormone then travels to your liver, which converts it into something called IGF-1, which is insulin-like growth factor 1, the actual downstream signal that drives most of the tissue-level effects people care about. The peptides we're talking about here, CJC-1295, tesamorelin, and ipamorelin, are all working at that first step: convincing your pituitary to release more growth hormone. But they're knocking on completely different doors.

Ipamorelin works by binding to what are called ghrelin receptors, which are the same receptors your body uses to process ghrelin, a hormone naturally associated with hunger and growth hormone pulsation. CJC-1295 and tesamorelin work by binding to GHRH receptors, which stands for growth hormone releasing hormone receptors, a completely separate receptor family that responds to a completely different signal.

Why does the distinction matter? Because receptors are not static. They respond to how much they're being stimulated.

When a receptor gets activated over and over without a break, your body does something called beta-arrestin mediated internalization, which is a process where the cell literally pulls the receptor off its surface and brings it inside, effectively reducing the number of available docking stations for the next signal. Think of it like a restaurant that starts locking the doors when it gets overwhelmed. The capacity doesn't disappear permanently, but it's temporarily offline.

Ghrelin receptors do this with continuous stimulation. A 16-week human trial tracked growth hormone response in people receiving continuous ghrelin receptor stimulation, and by week 16 the growth hormone response had dropped roughly 45 percent from where it started. When they stopped for four weeks, the response came all the way back to baseline. That's the clearest human evidence we have for receptor desensitization in this context, and it's exactly why protocols that include ipamorelin typically run about three months on and one month off.

Now here's where people get the cycling logic wrong.

Because ipamorelin is almost always sold combined with CJC-1295 in the same vial, people assume both peptides share the same cycling requirement. The cycling advice spreads as a single rule because the combination spreads as a single product. But when you look at the GHRH receptor system separately, the data tells a different story.

Tesamorelin is a stabilized analog of GHRH, meaning it works through those GHRH receptors, not ghrelin receptors. In the Phase 3 clinical trials that led to FDA approval, patients received daily tesamorelin injections for 52 consecutive weeks. IGF-1 levels held steady across that entire period with no meaningful decline. There was no desensitization signal in the data. VAT reduction, which is the visceral fat reduction that was the primary endpoint, also held through the full 52 weeks.

The reason GHRH receptor systems behave differently here comes down to pharmacokinetics, which is just the study of how a drug moves through your body over time. Tesamorelin has a half-life of roughly 26 to 38 minutes. You inject it, it binds to GHRH receptors and triggers a growth hormone pulse, and then it's cleared from your system within about 30 to 40 minutes. That means your GHRH receptors get a brief, sharp signal and then have the remaining 23-plus hours before your next dose to sit completely unstimulated.

That recovery window appears to be enough to prevent the kind of internalization you see with ghrelin receptors under typical dosing patterns.

A bench study using perifused rat pituitary cells confirmed something important here: the GHRH receptor system and the ghrelin receptor system are functionally independent, meaning desensitizing one does not desensitize the other, and they can actually be stimulated simultaneously to get additive growth hormone output. That independence is the whole mechanistic basis for why combination peptides work at all, and it's also the basis for why they shouldn't necessarily cycle the same way.

There's an additional data point worth noting from the ghrelin receptor side. MK-677, an oral ghrelin mimetic that activates the same receptors as ipamorelin, was studied over two years of continuous daily use in healthy older adults and maintained elevated GH and IGF-1 throughout the study period. That seems to contradict the 16-week desensitization data at first glance, but the difference is likely in the pattern of stimulation. MK-677's oral pharmacokinetics produce a different receptor occupancy curve than frequent subcutaneous peptide dosing, which may create enough natural variation in receptor stimulation to prevent the same degree of internalization. The mechanism isn't fully resolved, so this point sits in the theoretical category rather than settled science.

What this means practically is straightforward. If you're running a combination of CJC-1295 and ipamorelin, the reason to cycle is the ipamorelin. The ghrelin receptor desensitization is real, it's documented in humans, and the three-months-on one-month-off structure exists to let those receptors recover. The CJC component is along for the ride on that cycle, not driving it.

If you're running tesamorelin alone, there is no published clinical evidence that says you need to cycle it. The 52-week FDA trial is the longest continuous human dataset we have, and it showed no drop-off. That doesn't mean indefinite use is without any consideration, but it means the cycling requirement that applies to ghrelin-based peptides does not carry over by default.

The real issue isn't which peptide to cycle. It's that most cycling advice was built around a combination product and then applied backwards to the individual components. The receptor systems are not the same thing, so the rules shouldn't be either.

---

References

1. Rahim A, Shalet SM. Does desensitization to hexarelin occur? Growth Horm IGF Res. 1998;8 Suppl B:141-143 — 16-week human trial showing 45% GH response decline with continuous ghrelin receptor stimulation, full recovery after 4 weeks off. Source
2. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM. 2007 — Tesamorelin daily dosing for 26 weeks with sustained IGF-1 elevation. Source
3. FDA Prescribing Information. EGRIFTA (tesamorelin). 2010/2025 — 52-week pooled Phase 3 data showing sustained IGF-1 and VAT reduction through week 52
4. Blake AD, Smith RG. Desensitization studies using perifused rat pituitary cells. J Endocrinol. 1991;1291:11-19 — Proved GHRH and ghrelin receptor systems are independent with no cross-desensitization. Source
5. Nass R et al. Effects of an oral ghrelin mimetic on body composition in healthy older adults. Ann Intern Med. 2008;1499:601-611 — MK-677 ghrelin mimetic maintained GH/IGF-1 elevation for 2 years of continuous use. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness